Clinical results of accelerated hypofractionated radiotherapy for central-type small lung tumours.
Curr Oncol
; 24(4): e285-e289, 2017 Aug.
Article
in En
| MEDLINE
| ID: mdl-28874899
ABSTRACT
PURPOSE:
We evaluated the efficacy and toxicity of accelerated hypofractionated radiotherapy (ahypof-rt) for central-type small lung tumours.METHODS:
Between November 2006 and January 2015, 40 patients with central-type small lung tumours underwent ahypof-rt delivered using 10 MV X-rays and a coplanar 3-field technique. The number of fractions ranged from 24 to 28, with a fraction size of 2.5-3 Gy. A total dose of 69-75 Gy to the isocentre of the planning target volume was administered to each patient. Cumulative survival and local control rates were calculated using the Kaplan-Meier method.RESULTS:
The 27 men and 13 women enrolled in the study had a median age of 79 years (range 60-87 years). The tumour stage was T1a in 9 patients, T1b in 17 patients, and T2a in 14 patients, with a median size of 26.5 cm (range 11-49 cm). The median follow-up period was 23 months. A complete response was achieved in 3 patients (7.5%), and a partial response, in 17 patients (42.5%). The overall 2-year and 3-year local control rates were 87.3% and 81.8% respectively; the 2-year and 3-year overall survival rates were 78.9% and 66.7% respectively. Grade 3 pneumonitis occurred in 3 patients; no other severe adverse events (≥grade 3) were observed in any patient.CONCLUSIONS:
Accelerated hypofractionated radiotherapy using a fraction size of 2.5-3 Gy was highly safe and can be a more effective treatment option than conventional radiotherapy for patients with central-type small lung tumours.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Curr Oncol
Year:
2017
Document type:
Article